Pediatric Malignancy-Associated HLH: Clinical Data for 44 Patients, 2003-2024

44 pediatric patient records from a retrospective, single-center cohort study investigating malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH). The dataset likely contains clinical characteristics, treatment regimens, and survival outcomes for patients diagnosed between January 2003 and December 2024. It was authored by Chengshuang Huang and shared via figshare.

Use Cases

• Analyze prognostic factors for pediatric M-HLH based on clinical characteristics like age, serum ferritin, and lactate dehydrogenase.
• Compare survival outcomes between HLH at malignancy diagnosis and HLH after chemotherapy based on patient subgroups.
• Identify associations between cytokine levels (IL-2R, IFN-γ, TNF-α) and HLH subtypes based on laboratory data.
• Evaluate treatment efficacy based on overall response rate (ORR) and overall survival (OS) metrics.

Strengths

• Includes 44 patient records with a median age of 6.63 years and a defined time range from 2003 to 2024.
• Contains specific clinical outcomes such as 6-month, 1-year, and 2-year overall survival rates (79%, 69%, 67%).
• Provides detailed breakdowns of malignancy types (56.8% lymphoma, 27.3% acute leukemia, 15.9% Langerhans cell histiocytosis).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is from a single-center study, which may reflect institutional-specific treatment protocols and patient demographics.

Provenance

Source

figshare

Collection Method

Retrospective, single-center cohort study.

Time Range

January 2003 to December 2024

Freshness

Last updated 2026-05-07 04:37:08; freshness should be verified.